Skye Bioscience, Inc. Common Stock (SKYE) Stock Forecast
Show ratings and price targets of :
Alert
Its only available to paid users.
USD 18.17
(+537.43%)
Based on the Skye Bioscience, Inc. Common Stock stock forecast from 6 analysts, the average analyst target price for Skye Bioscience, Inc. Common Stock is USD 18.17 over the next 12 months. Skye Bioscience, Inc. Common Stock’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Skye Bioscience, Inc. Common Stock is Very Bearish, which is based on 0 positive signals and 3 negative signals. At the last closing, Skye Bioscience, Inc. Common Stock’s stock price was USD 2.85. Skye Bioscience, Inc. Common Stock’s stock price has changed by -2.06% over the past week, +2.89% over the past month and -55.54% over the last year.
No recent analyst target price found for Skye Bioscience, Inc. Common Stock
No recent average analyst rating found for Skye Bioscience, Inc. Common Stock
Company Overview Skye Bioscience, Inc. Common Stock
Skye Bioscience, Inc., a biopharmaceutical company, focuses on unlocking new therapeutic pathways for metabolic health through the development of molecules that modulate G-protein coupled receptors. The company is conducting a Phase 2 clinical trial in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy). The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California. Read Less
Skye Bioscience, Inc., a biopharmaceutical company, focuses on unlocking new therapeutic pathways for metabolic health through the development of molecules that modulate G-protein coupled receptors. The company is conducting a Phase 2 clinical trial in obesity for nimacimab, a ne...Read More
Frequently Asked Questions About Skye Bioscience, Inc. Common Stock (SKYE) Stock
Based on ratings from 6 analysts Skye Bioscience, Inc. Common Stock's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 12 buy, sell and hold ratings.
Unfortunately we do not have enough data on SKYE's stock to indicate if its a good dividend stock.
Based on targets from 6 analysts, the average taret price for SKYE is USD 18.17 over the next 12 months. The maximum analyst target price is USD 21 while the minimum anlayst target price is USD 14.
Unfortunately we do not have enough data on SKYE's stock to indicate if its overvalued.
The last closing price of SKYE's stock was USD 2.85.
The most recent market capitalization for SKYE is USD 0.16B.
Based on targets from 6 analysts, the average taret price for SKYE is projected at USD 18.17 over the next 12 months.
This means that SKYE's stock price may go up by +537.43% over the next 12 months.
We can't find any ETFs which contains Skye Bioscience, Inc. Common Stock's stock.
As per our most recent records Skye Bioscience, Inc. Common Stock has 11 Employees.
Skye Bioscience, Inc. Common Stock's registered address is 11250 El Camino Real, San Diego, CA, United States, 92130.
You can get more information about it from Skye Bioscience, Inc. Common Stock's website at https://skyebioscience.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About Skye Bioscience, Inc. Common Stock (SKYE) Stock
Based on ratings from 6 analysts Skye Bioscience, Inc. Common Stock's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 12 buy, sell and hold ratings.
Unfortunately we do not have enough data on SKYE's stock to indicate if its a good dividend stock.
Based on targets from 6 analysts, the average taret price for SKYE is USD 18.17 over the next 12 months. The maximum analyst target price is USD 21 while the minimum anlayst target price is USD 14.
Unfortunately we do not have enough data on SKYE's stock to indicate if its overvalued.
The last closing price of SKYE's stock was USD 2.85.
The most recent market capitalization for SKYE is USD 0.16B.
Based on targets from 6 analysts, the average taret price for SKYE is projected at USD 18.17 over the next 12 months.
This means that SKYE's stock price may go up by +537.43% over the next 12 months.
We can't find any ETFs which contains Skye Bioscience, Inc. Common Stock's stock.
As per our most recent records Skye Bioscience, Inc. Common Stock has 11 Employees.
Skye Bioscience, Inc. Common Stock's registered address is 11250 El Camino Real, San Diego, CA, United States, 92130.
You can get more information about it from Skye Bioscience, Inc. Common Stock's website at https://skyebioscience.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for SKYE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
